The short answer
Pramlintide is a synthetic analogue of human amylin and the first to reach clinical use. Human amylin aggregates into amyloid fibrils, making it undeliverable; pramlintide substitutes three residues with prolines borrowed from rat amylin, which does not aggregate. Its short half-life required dosing with meals.
Key facts
- Class
- Amylin analogue
- Molecular weight
- ~3,949 Da
- Molecular formula
- C171H267N51O53S2
- PubChem CID
- 70691388
- Parent hormone
- Human amylin (37 residues)
- Key modification
- Proline substitutions from rat amylin
- Dosing
- With meals (short half-life)
- Successor
- Cagrilintide (weekly)
The aggregation problem
Human amylin has a strong propensity to self-assemble into amyloid fibrils. This is not merely a formulation nuisance: it is the same process that deposits islet amyloid in the pancreas in type 2 diabetes. A peptide that turns into insoluble fibrils cannot be delivered reliably, so aggregation had to be solved before amylin pharmacology could be used at all.
The solution came from rodents
Rat amylin does not form amyloid, and the difference traces to a small number of residues in the aggregation-prone region. Pramlintide substitutes prolines at those positions, borrowing rat amylin's resistance. Proline disrupts the regular backbone geometry that β-sheet amyloid assembly requires, so the substitution removes the capacity to fibrillise while retaining receptor activity.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why it needed meal-time dosing
Pramlintide has a short half-life and no half-life extension technology: no fatty acid, no albumin binding. Amylin's physiological role is meal-associated, so meal-time dosing matched the biology, but it meant multiple injections a day alongside insulin. That practical burden limited uptake regardless of pharmacology.
What changed with cagrilintide
Cagrilintide is engineered for once-weekly administration, which brings amylin into the same dosing rhythm as modern GLP-1 analogues. That is what makes a fixed-dose weekly combination such as CagriSema possible. Pairing a weekly GLP-1 agonist with a meal-time amylin analogue would not be a practical product.
Why pramlintide matters historically
It established that amylin receptor agonism was achievable and tolerable in people, and that the aggregation barrier could be engineered around. Everything in the current amylin combination pipeline (cagrilintide, amycretin) rests on that being settled two decades earlier.
Frequently asked questions
Is pramlintide a GLP-1 drug?
No. It is an amylin analogue, acting at the amylin receptor complex through a satiety pathway distinct from GLP-1's.
Why does human amylin form amyloid but rat amylin does not?
A small number of residue differences in the aggregation-prone region. Pramlintide borrows rat amylin's prolines at those positions.
How does pramlintide differ from cagrilintide?
Pramlintide is short-acting and dosed with meals. Cagrilintide is engineered for weekly administration, which makes weekly combination products possible.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Pramlintide (CID 70691388)pubchem.ncbi.nlm.nih.gov
- PubMedSecher A et al., The story of amylin: from physiology to therapy. Nat Metab 2026 (PMID 41708975)pubmed.ncbi.nlm.nih.gov
- PubMedVolčanšek Š et al., Amylin: from mode of action to clinical potential. Diabetes Ther 2025 (PMID 40332747)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Oxyntomodulin? Nature's Dual AgonistOxyntomodulin is a gut peptide that activates both GLP-1 and glucagon receptors. It is the biological precedent every GLP-1/glucagon dual agonist is built on.
- GLP-1 Agonists and Alcohol Use: The Trial EvidenceThree randomised trials have tested semaglutide in alcohol use disorder, reporting reduced craving and heavy drinking days. All were small and short.
- SURMOUNT-OSA: Tirzepatide in Obstructive Sleep ApnoeaTirzepatide reduced apnoea-hypopnoea index by 27.4 events per hour at 52 weeks against 4.8 on placebo. The first incretin approved for a non-metabolic use.
- Why GLP-1 Receptors Turn Up in Reward ResearchGLP-1 receptors are expressed in mesolimbic reward circuitry, not only in appetite regions. That expression is the mechanistic basis for the craving findings.
- Why GLP-1 Drugs Matter Before AnaesthesiaDelayed gastric emptying means a fasted patient on a GLP-1 may still have stomach contents. Ultrasound studies, and why this is a mechanism-linked risk.